NCT04597411 - Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

RADIATION

225^Ac-PSMA-617

administered intravenously under the dose escalation schedule

RADIATION

68^Ga-PSMA-11

administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)

Trial Locations (2)

RECRUITING

St. Vincent's Hospital Research Office-Translational Research Center, Darlinghurst

RECRUITING

Steve Biko Hospital-Department of Nuclear Medicine, Pretoria